The American Journal of Pathology, Vol. 177, No. 1, July 2010
Copyright © American Society for Investigative Pathology
DOI: 10.2353/ajpath.2010.091176
Molecular Pathogenesis of Genetic and Inherited Diseases
Matrix Metalloproteinase Inhibitor Batimastat
Alleviates Pathology and Improves Skeletal Muscle
Function in Dystrophin-Deficient mdx Mice
Akhilesh Kumar, Shephali Bhatnagar,
and Ashok Kumar
From the Department of Anatomical Sciences and Neurobiology,
University of Louisville School of Medicine, Louisville, Kentucky
Duchenne muscular dystrophy (DMD), caused by mutations in the dystrophin gene, involves severe muscle degeneration, inflammation, fibrosis, and early
death in afflicted boys. Matrix metalloproteinases
(MMPs) are extracellular proteases that cause tissue
degradation in several disease states. In this study, we
tested the hypothesis that the expression levels of
various MMPs are abnormally increased and that their
inhibition will ameliorate muscle pathogenesis in
animal models of DMD. Our results show that the
transcript levels of several MMPs are significantly upregulated, whereas tissue inhibitors of MMPs are
down-regulated, in dystrophic muscle of mdx mice.
Chronic administration of batimastat (BB-94), a broad
spectrum peptide inhibitor of MMPs, reduced necrosis, infiltration of macrophages, centronucleated fibers, and the expression of embryonic myosin heavy
chain in skeletal muscle of mdx mice. Batimastat also
reduced the expression of several inflammatory molecules and augmented the levels of sarcolemmal protein -dystroglycan and neuronal nitric oxide in mdx
mice. In addition, muscle force production in isometric
contraction was increased in batimastat-treated mdx
mice compared with those treated with vehicle alone.
Furthermore, inhibition of MMPs using batimastat reduced the activation of mitogen-activated protein kinases and activator protein-1 in myofibers of mdx mice.
Our study provides the novel evidence that the expression of MMPs is atypically increased in DMD ,
that their inhibition ameliorates pathogenesis , and
that batimastat could prove to be a significant candidate
for DMD therapy. (Am J Pathol 2010, 177:248 –260; DOI:
10.2353/ajpath.2010.091176)
Duchenne muscular dystrophy (DMD) is a devastating
genetic disorder of skeletal muscle caused by complete
248
or partial deficiency of dystrophin.1,2 Dystrophin is an
integral component of the transmembrane protein network known as dystrophin-glycoprotein complex (DGC)
in sarcolemma, which not only provides mechanical
stability but also serves as an important signaling link
between extracellular matrix stimuli and intracellular
components of skeletal muscle.3,4 Loss of functional dystrophin protein makes sarcolemma fragile, resulting in
ready damage during muscle contraction leading to the
initiation of inflammatory response, degradation of the
components of cytoskeletal-extracellular matrix (ECM)
network, and fiber necrosis.5 Lack of dystrophin protein
on sarcolemma also results in the aberrant activation of
many proinflammatory signal transduction pathways in
skeletal muscle, which contributes to pathogenesis.4,6 – 8
However, despite major progress in understanding the
pathophysiological mechanisms, there is still no therapy
available for DMD patients.
Studies in the recent past have demonstrated that
secondary events such as inflammation, cycles of fiber
degeneration and regeneration, and fibrosis contribute
actively to skeletal muscle pathogenesis in DMD.6,7,9,10
Matrix metalloproteinases (MMPs) are a family of zincdependent endopeptidases that play an important role in
ECM degradation, inflammation, fibrosis, and activation
of latent cytokines and cell adhesion molecules in different pathophysiological conditions.11 MMPs are synthesized as secreted or transmembrane proenzymes and
then processed to an active enzyme by the removal of an
amino-terminal propeptide.11,12 Abnormal increase in
MMP levels has been found to contribute to tissue destruction in many pathological conditions such as chronic
wounds, heart failure, rheumatic arthritis, fibrotic lung
disease, dilated cardiomyopathy, asthma, gastric ulcer,
central nervous system diseases, multiple sclerosis, and
Supported in part by Institutional Start-Up Funds and a National Institutes
of Health grant R01 AG129623 (A.K.).
Accepted for publication March 12, 2010.
Address reprint requests to Ashok Kumar, Ph.D., Associate Professor,
Department of Anatomical Sciences and Neurobiology, University of Louisville School of Medicine, 500 South Preston Street, Louisville, KY 40202.
E-mail: ashok.kumar@louisville.edu.
Batimastat Inhibits Pathology in mdx Mice
249
AJP July 2010, Vol. 177, No. 1
cancer.11,13–17 Recent studies using transgenic and
knockout mouse models have further revealed that MMPs
also play critical roles in various physiological processes
such as development, cell migration, and release of
growth factors during tissue repair, as well as participate
in host protective mechanisms.11,12 Furthermore, the role
of individual MMPs has been found to be dependent on
stages of disease progression, suggesting that MMP inhibition can have both advantageous and disadvantageous consequences.18,19 The contribution of MMPs in
physiological processes has also been highlighted by the
observations that several broad-spectrum MMP inhibitory
drugs failed in multiple clinical trials for various types of
cancer.19 However, the potential role of MMPs in skeletal
muscle loss and whether the inhibition of MMPs can be
used as therapeutic option in muscular dystrophy patients are not yet investigated.
We recently reported that the expression of MMP-9 (gelatinase B) is increased in dystrophic muscle and genetic
ablation of MMP-9 considerably reduces inflammatory response, fibrosis, and enhances the regeneration of myofibers in mdx mice (a murine model of DMD).20 However,
accumulating evidence also suggests that there is a cooperative interaction between various MMPs to regulate tissue
degradation in different physiological and pathophysiological conditions. The members of the MMPs family often
activate each other, for example, membrane type 1 metalloproteinase (MT1-MMP) activates MMP-2 or MMP-13 and
MMP-3 activates MMP-9.11,12,21 However, it remains unknown how the levels and the activities of various MMPs
other than MMP-9 are regulated in skeletal muscle of mdx
mice. Furthermore, it remains unknown whether MMP inhibitory molecules can improve skeletal muscle pathology in
animal models of DMD.
Because MMPs are strongly linked to tissue degradation
in several disease states, in the past decade, a number of
pharmacological compounds/drugs have been developed
that can block the activity of a specific or multiple MMPs in
animal models and humans.18 Batimastat (BB-94) and it’s
orally bioavailable derivative marimastat, are collagen peptide-based hydroxamic acids. These were among the first
synthetic MMP inhibitors evaluated to treat cancer.18,19
Batimastat mimics the site in the collagen substrate that is
cleaved by the MMPs and works by a competitive, reversible inhibition.22,23 It is one of the most important
broad-spectrum MMP inhibitors, effectively blocking the
activities of MMP-1 (MMP-13 in rats), MMP-2, MMP-3,
MMP-7, MMP-8, MMP-9, and MMP-14.22–24 Batimastat
and marimastat have been reported to inhibit growth,
invasion, and metastasis as well as to prolong survival in
rodent cancer models.23,25–28 While batimastat and marimastat were found to show beneficial effects in Phase II
and III trials in some type of cancer patients, so far no
clinical trial has been considered as successful because
of deleterious side effects.19,29 –34 However, it is noteworthy that cancer is a highly complex disorder involving
multiple factors. Furthermore, all of the clinical trials using
MMP inhibitors were performed in advanced stage cancer patients where the inhibition of MMPs might not be
sufficient to block growth and spread of malignant
cells.19 In contrast to cancer, DMD, a genetic disorder
caused due to mutations in a single gene (ie, dystrophin),
can be detected at an early stage, progresses in a much
milder fashion, and can be treated before the pathology
is fully established.
To understand the role of MMPs in the DMD, in this
study, we first investigated how the expression of various
MMPs and related molecules involved in ECM remodeling is affected in skeletal muscle of mdx mice. We have
also investigated the effects of chronic administration of
batimastat on skeletal muscle pathology and function in
mdx mice.
Materials and Methods
Animals and Treatment Protocol
Control (strain C57BL10/ScSn) and mdx (strain
C57BL10ScSn DMDmdx) mice were purchased from
Jackson Laboratory (Bar Harbor, ME). Control and mdx
mice were treated with batimastat (BB-94) using a protocol as described.35 Starting at the age of 2 weeks, control
and mdx mice were given intraperitoneal injections of
batimastat (30 mg/kg as a suspension of 3 mg/ml in
phosphate-buffered saline containing 0.01% Tween 80)
three times a week for a total of 5 weeks. Batimastat
untreated mice received the same volume of vehicle
alone. After 24 hours of final administration of batimastat,
the mice were sacrificed and skeletal muscles were isolated and analyzed. All experiments with animals were
approved by the Institutional Animal Care and Use Committee of the University of Louisville.
PCR Array Analysis
RNeasy Mini Kit (Qiagen) was used to extract total RNA
from skeletal muscle tissues36 and contaminating DNA
was removed using the DNA-free kit from Ambion (Austin,
TX). Quality and quantity of RNA were analyzed using an
Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA) and
NanoDrop instrumentation (NanoDrop Technologies, Wilmington, DE). Purified RNA (1 g) was used to synthesize
first strand cDNA by reverse transcription system using
Ambion’s oligo(dT) primer and Qiagen’s Omniscript reverse transcriptase according to the manufacturer’s instructions. For the PCR array experiments, an RT2 Profiler
PCR Array (SABiosciences, Frederick, MD) was used to
simultaneously examine the mRNA levels of 89 genes,
including five housekeeping genes, in 96-well plates according to the manufacturer’s protocol. Equal amounts of
cDNA made from gastrocnemius muscle from four control or four mdx mice were pooled. Real-time PCR was
performed using an ABI Prism 7300 sequence detection
system (Applied Biosystems, Foster City, CA). Data analysis and fold change in gene expression values were
calculated using online software provided by the manufacturer (SABiosciences, Frederick, MD).
250
Kumar et al
AJP July 2010, Vol. 177, No. 1
Quantitative Real-Time PCR (QRT-PCR)
Real-time PCR for individual genes was performed using
an ABI Prism 7300 sequence detection system (Applied Biosystems) using a method as previously described.36,37 Briefly, the first-strand cDNA reaction (0.5
l) from gastrocnemius muscle of individual control or
mdx mice (n ⫽ 4 in each group) was subjected to realtime PCR amplification using gene-specific primers. The
primers were designed according to ABI primer express
instructions using Vector NTI software and were purchased from Sigma-Genosys (Spring, TX). The sequences of the primers used are as follows: MMP-3:
5⬘-GTGTGTGGTTGTGTGCTCATCCTA-3⬘ (forward) and
5⬘-CCCGAGGAACTTCTGCATTTCT-3⬘ (reverse); MMP10: 5⬘-GCATTCAATCCCTGTATGGAGC-3⬘ (forward) and
5⬘-TTCAGGCTCGGGATTCCAAT-3⬘ (reverse); MMP-14:
5⬘-ATTTGCTGAGGGTTTCCACG-3⬘ (forward) and 5⬘TCGGCAGAATCAAAGTGGGT-3⬘ (reverse); ICAM-1: 5⬘GGTGGTGAAGTCTGTCAAACAGGA-3⬘(forward) and 5⬘AACATAAGAGGCTGCCATCACG-3⬘ (reverse); VCAM-1:
5⬘-TCTATTTCACTCACACCAGCCCG-3⬘ (forward) and
5⬘-ATCCAAAGTACCGTTGAGGCTCC-3⬘ (reverse); Col1a1:
5⬘-TCAAGATGGTCGCCCTGGAC-3⬘ (forward) and
5⬘-CCTTTCCAGGTTCTCCAGCG-3 (reverse); Col3a1: 5⬘GTGAACGTGGCTCTAATGGCAT-3⬘ (forward) and 5⬘AATAGGACCTGGATGCCCACTT-3⬘ (reverse); TIMP-2:
5⬘-GTGACTTCATTGTGCCCTGGG-3⬘ (forward) and 5⬘TGGGACAGCGAGTGATCTTGC-3⬘ (reverse); TIMP-3: 5⬘CAGATGAAGATGTACCGAGGCTTC-3⬘ (forward) and
5⬘-AACCCAGGTGGTAGCGGTAATT-3⬘ (reverse); CD68:
5⬘-TTACTCTCCTGCCATCCTTCACGA-3⬘ (forward), and
5⬘-CCATTTGTGGTGGGAGAAACTGTG-3⬘ (reverse);
Mac-1: 5⬘-AGGGTTGTCCAGCCGATGATAT-3⬘ (forward),
and 5⬘-CCCAGCTTCTTGACGTTGTTGA-3⬘ (reverse);
TNF-␣, 5⬘-GCATGATCCGCGACGTGGAA-3⬘ (forward) and
5⬘-AGATCCATGCCGTTGGCCAG-3⬘ (reverse); Myogenin:
5⬘-CATCCAGTACATTGAGCGCCTA-3⬘ (forward) and 5⬘GAGCAAATGATCTCCTGGGTTG-3⬘ (reverse); -actin,
5⬘-CAGGCATTGCTGACAGGATG-3⬘ (forward) and 5⬘TGCTGATCCACATCTGCTGG-3⬘ (reverse); and MYH4 5⬘GGAACAGTATGAAGAGGAGCAGGA-3⬘ (forward), and 5⬘ATTCTGAAGTCGCTGCTTCGTC-3⬘ (reverse).
Real-time PCR assays were performed in approximately 25-l reactions, consisting of 2X (12.5 l) Brilliant
SYBR Green QPCR Master Mix (Stratagene), 400 nmol/L
primers (0.5 l each from the stock), 11 l of water, and
0.5 l of template. The thermal conditions consisted of an
initial denaturation at 95°C for 10 minutes followed by 40
cycles of denaturation at 95°C for 15 seconds, annealing
and extension at 60°C for 1 minute, and, for a final step,
a melting curve of 95°C for 15 seconds, 60°C for 15
seconds, and 95°C for 15 seconds. All reactions were
performed in triplicate to reduce variation. The data were
analyzed using SDS software version 2.0, and the results
were exported to Microsoft Excel for further analysis.
Data normalization was accomplished using two endogenous control (-actin) and myosin heavy chain 4
(MyHC4), and the normalized values were subjected to a
2⫺⌬⌬Ct formula to calculate the fold change between the
control and experimental groups. The formula and its
derivations were obtained from the ABI Prism 7900 sequence detection system user guide.
Western Blotting
Quantitative estimation of specific protein was done by
Western blot using a method as previously described.36
Briefly, skeletal muscle tissues were washed with PBS
and homogenized in lysis buffer A [50 mmol/L Tris-Cl (pH
8.0), 200 mmol/L NaCl, 50 mmol/L NaF, 1 mmol/L dithiothreitol, 1 mmol/L sodium orthovanadate, 0.3% IGEPAL,
and protease inhibitors]. Approximately 100 g of protein
was resolved on each lane on 8 –12% SDS-polyacrylamide gel electrophoresis, electrotransferred onto nitrocellulose membrane and probed using anti--dystroglycan (1:500, Santa Cruz), anti– embryonic myosin heavy
chain (E-MyHC) (1:100, Developmental Studies Hybridoma Bank), anti-utrophin (1:100; Developmental Studies
Hybridoma Bank), anti-␣-dystroglycan (Santa Cruz), anti␣-dystrobrevin (1:500; Santa Cruz), anti–neuronal nitric
oxide synthase (nNOS) (1:500; Santa Cruz), anti-phospho-p44/p42 (1:1000, cell Signaling), anti-phosphoJNK1/2 (1:1000, Cell signaling, Inc), anti-phospho-p38
(1:500, Santa Cruz), anti-total p44/p42 (1:1000, Cell
Signaling, Inc), anti-total JNK1/2 (1:1000, Santa Cruz),
anti-total p38 (1:1000, Cell Signaling, Inc.), and anti-␣tubulin (1:2000, Cell Signaling, Inc.) and detected by
chemiluminescence.
MMP Assays
Fold difference in MMPs enzymatic activity was determined using the Sensolyte 520 Generic MMP Assay Kit,
which measures the activity of a variety of MMPs, including MMP-1, 2, 3, 7, 8, 9, 12, 13, and 14 (AnaSpec,
Fremont, CA). Briefly, skeletal muscle extracts were prepared in lysis buffer A and 100 g protein lysates were
incubated with the FAM/QXL 520 fluorescence resonance energy transfer substrate for 1 hour in a black
96-well plate at room temperature in the dark. Measurements were made using SpectraMax M5 microplate
reader (excitation at 490 nm, emission at 520 nm).
Electrophoretic Mobility Shift Assay
The DNA binding activity of the AP-1 transcription factor
was measured using electrophoretic mobility shift assay
as detailed previously.4 Briefly, 25 g of nuclear extract
prepared from skeletal muscle was incubated with 16
fmol [32P]␥-ATP end-labeled AP-1 consensus doublestranded oligonucleotide (Promega, MA) for 20 minutes
at 37°C. The incubation mixture included 2 to 3 g of poly
dI.dC in a binding buffer (25 mmol/L HEPES, pH 7.9, 0.5
mmol/L EDTA, 0.5 mmol/L dithiothreitol, 1% IGEPAL, 5%
glycerol, 50 mmol/L NaCl). The DNA-protein complex
thus formed was separated from free oligonucleotides on
a 7.5% native polyacrylamide gel. The gel was dried, and
radioactive bands were visualized and quantitated by
PhosphorImager using ImageQuant TL software (GE
Health care, Piscataway, NJ).
Batimastat Inhibits Pathology in mdx Mice 251
AJP July 2010, Vol. 177, No. 1
Histomorphometric and Immunofluorescence
Studies
Serial cross-sections (10 m thick) from mid-belly of frozen skeletal muscle tissues were mounted on glass slides
and stained for H&E using standard protocol.20 Pictures
of the whole muscle sections were captured and the
percentage of centrally nucleated fibers was counted in
the entire muscle section. To quantify the variation in fiber
size, fiber cross-sectional area was measured for every
fiber in each section using Nikon NIS Elements BR 3.00
software (Nikon). Variability in cross-sectional areas between samples was expressed as the mean of the standard deviations for each population. The extent of fibrosis
in muscle cryosections was determined using a Sirius red
dye staining kit following a protocol suggested by manufacturer (American Master Tech).
For immunofluorescence staining, muscle sections
were fixed in acetone for 10 minutes and air dried. The
sections were blocked in 1% bovine serum albumin in
PBS for 1 hour, and incubated with primary antibody in
blocking solution at 4°C overnight under humidified conditions. The sections were washed three times with PBS
before incubation with secondary antibody for 1 hour at
room temperature and then washed three times for 30
minutes each with PBS. The slides were mounted using
fluorescence medium with DAPI (Vector Laboratories),
visualized under a fluorescent microscope (Nikon) and
images were captured using Nikon DS Fi1 camera
(Nikon). The dilution and source of primary antibodies are
as follows: Anti-Mac-1 (1:100, Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA), antilaminin (1:100, Sigma), and anti-E-MyHC (1:50, Developmental Studies Hybridoma Bank, University of Iowa).
Alexa Fluor 488 or Alexa Fluor 596-conjugated secondary
antibodies were obtained from Invitrogen and used at
1:3000 dilutions.
To study the effects of batimastat on sarcolemmal
permeability and fiber necrosis, muscle sections were
stained with Cy3-labeled goat anti-mouse IgG (Invitrogen) and the number of IgG-filled fibers in two different
sections of each gastrocnemius muscle (two muscles
from each mouse) was counted as described.20 Data are
presented as average number of permeable/damaged
fibers per muscle section.
Skeletal Muscle Functional Studies
The force production in isometric contractions was measured using a similar method as described.20 After anesthetizing the mice, intact diaphragm was isolated and
immediately placed into a muscle bath with continuously
circulating oxygenated 95% O2⫺5% CO2 Krebs-Ringer
solution (in mmol/L: 135 NaCl, 5 KCl, 2.5 CaCl2, 1 MgSO4,
1 NaH2PO4, 15 NaHCO3 and 11 glucose). A muscle strip
(2 mm in width) from the costal region of the diaphragm
was excised under a stereomicroscope and transferred
to 37°C oxygenated Krebs-Ringer solution for equilibration for 15 minutes before contractile studies. The muscle
was mounted between a Fort25 force transducer (World
Precision Instrumentation) and a micromanipulator
device in a temperature-controlled myobath (World
Precision Instrumentation). The muscle was positioned
between platinum wire stimulating electrodes and stimulated to contract isometrically using electrical field stimulation (supramaximal voltage, 1.2 ms pulse duration)
using a Grass S88 stimulator. In each experiment, muscle
length was adjusted to optimize twitch force (optimal
length, Lo). The output of the force transducer was recorded in computer using LAB-TRAX-4 software. To investigate a potentially different frequency response between groups, titanic contractions were assessed by
sequential stimulation at 25, 50, 75, 100, 150, 200, and
300 Hz with 2 minutes of rest in between. The crosssectional area for each muscle was determined by dividing muscle weight by its length and tissue density (1.06
g/L), and muscle force was compared after correction for
cross-sectional area.
Statistical Significance
Results are expressed as mean ⫾ SD. Statistical analysis
used Student’s t-test to compare quantitative data populations with normal distribution and equal variance. A
value of P ⬍ 0.05 was considered statistically significant
unless otherwise specified.
Results
Expressions and Activities of Various MMPs Are
Increased in Skeletal Muscle of mdx Mice
We first studied the expression levels of various MMPs
and related genes in skeletal muscle of mdx mice using a
PCR gene array technique (SABiosciences, Frederick,
MD) that examined the mRNA levels of 89 genes. Analyses of PCR arrays revealed that mRNA levels of several
MMPs (eg, MMP-3, -8, -9, -10, -12, -13, -14, and -15) were
increased, although MMP-11 showed down-regulation in
gastrocnemius muscle of mdx mice in comparison with
control mice (Table 1). The expression of a disintegrin
and metallopeptidase (reprolysin type) with thrombospondin type 1 motif (Adamts) proteases, which are
also involved in remodeling processes, was also found to
be differentially regulated. Whereas the expression of
Adamts1, Adamts5, and Adamts8 were reduced, the
transcript level of Adamts2 was increased in gastrocnemius muscle of mdx mice compared with control mice
(Table 1). Out of four known physiological inhibitors of
MMPs (TIMPs), mRNA levels of TIMP-2 and TIMP-3 were
reduced and the expression of TIMP-1 was enhanced in
mdx mice compared with control mice. Furthermore, the
mRNA levels of several cell adhesion molecules (eg,
NCAM1, NCAM2, ICAM1, VCAM1, and L-selectin/Sel1)
and connective tissue growth factor (Ctgf) were increased in gastrocnemius muscle of mdx mice compared
with controls. The expression of several collagen genes
(eg, Col1a1, Col3a1, Col4a1, Col4a2, and Col5a1) was
increased in gastrocnemius muscle of mdx mice (Table
1). In contrast, the expression of Col2a1 and Col4a3
252
Kumar et al
AJP July 2010, Vol. 177, No. 1
diminished in dystrophic muscle of mdx mice compared
with controls (Table 1).
To validate the results of PCR array experiment, we
performed QRT-PCR for a few MMP-related genes on
gastrocnemius muscle of individual control and mdx
mice. As shown in Figure 1A, QRT-PCR results showed
good correlation with PCR array experiment. The transcript levels of MMP-3, MMP-10, MMP-14, VCAM-1,
Col1a1, and col3a1 were significantly higher, whereas
the mRNA levels of TIMP-2 were significantly lower in mdx
mice compared with control mice (Figure 1A). We next
sought to determine whether enzymatic activity of MMPs
was also similarly increased in skeletal muscle of mdx
mice. To determine the activities of MMPs, we used a
commercially available fluorescence-based MMPs assay
kit (AnaSpec, Fremont, CA). The kit measures the activities of a variety of MMPs including MMP-1, -2, -7, -8, -9,
-10, -13, and -14. Consistent with the increased expressions of several MMPs, the enzymatic activities of MMPs
were also found to be significantly higher in gastrocnemius muscle of mdx mice compared with the agematched control mice (Figure 1B). Similar increased expressions and activities of MMPs were also observed in
tibial anterior muscle of mdx mice (data not shown).
Taken together, these results provide strong evidence
that the expressions and activities of MMPs are dysregulated in dystrophic muscle of mdx mice.
Control;
1.5
0.5
0.0
MyHC
3.0
*
2.5
2.0
*
1.5
1.0
0.5
0.0
1.6
β-Actin
Mdx
1.2
0.8
0.4
*
*
0.0
β-Actin
MyHC
8
7
6
5
4
3
2
1
0
β-Actin
MyHC
Control;
Mdx
*
4
*
3
2
1
0
β-Actin
MyHC
5
*
*
β-Actin
MyHC
Control;
*
1.0
MyHC
*
4
*
3
2
1
0
β-Actin
MyHC
B
MMP’s enzymatic activity
(Relative light units)
β-Actin
5
*
2.0
MMP-14 Expression ratio
*
Mdx
2.5
Col3a1 Expression ratio
*
MMP-10 Expression ratio
⫺2.6
1.72
⫺1.43
⫺1.31
3.37
⫺1.28
2.75
1.53
1.18
⫺1.82
1.26
1.34
1.53
1.59
1.22
2.89
1.45
1.91
1.11
2.78
1.16
⫺1.41
1.33
1.41
2.76
1.11
3.1
⫺1.54
⫺2.02
9
8
7
6
5
4
3
2
1
0
Col1a1 Expression ratio
NM_009621
NM_175643
NM_011782
NM_013906
NM_007742
NM_031163
NM_009930
NM_009931
NM_009932
NM_007734
NM_015734
NM_010217
NM_010875
NM_010954
NM_010493
NM_011693
NM_011346
NM_010809
NM_008611
NM_013599
NM_019471
NM_008606
NM_008605
NM_008607
NM_008608
NM_008609
NM_011593
NM_011594
NM_011595
Fold
change
MMP-3 Expression ratio
Adamts1
Adamts2
Adamts5
Adamts8
Col1a1
Col2a1
Col3a1
Col4a1
Col4a2
Col4a3
Col5a1
Ctgf
Ncam1
Ncam2
Icam1
Vcam1
Sell
Mmp3
Mmp8
Mmp9
Mmp10
Mmp11
Mmp12
Mmp13
Mmp14
Mmp15
Timp1
Timp2
Timp3
GenBank
accession no.
VCAM-1 Expression ratio
Gene
symbol
A
TIMP-2 Expression ratio
Table 1. Fold Changes in mRNA Levels of Various MMPs
and Related Genes in Gastrocnemius Muscle of 6Week-Old mdx Mice Compared to Control Mice
Determined by PCR Gene Array Technique
40000
*
30000
20000
10000
0
Control
Mdx
Figure 1. Increased expression of MMPs, cell adhesion molecules, and
collagens in skeletal muscle of mdx mice. A: Gastrocnemius muscle from
6-week-old control and mdx mice were isolated and used to study the mRNA
levels of MMP-3, MMP-10, MMP-14, VCAM-1, Col1a1, Col3a1, and TIMP-2.
Data presented here show that the mRNA levels of MMP-3, MMP-10, MMP-14,
VACM-1, Col1a1, and Col3a1 were significantly increased, whereas mRNA
levels of TIMP-2 were significantly reduced in gastrocnemius muscle of mdx
mice (N ⫽ 4) compared with control mice (N ⫽ 4). The mRNA levels were
normalized using -actin and MyHC as housekeeping genes. B: Data presented here show that the enzymatic activity of MMPs is significantly increased in gastrocnemius muscle of mdx mice compared with control mice.
*P ⬍ 0.01, values significantly different from wild-type mice.
Batimastat Improves Skeletal Muscle Structure
and Reduces Fibrosis in mdx Mice
Control and mdx mice were given chronic administration
of batimastat, a broad spectrum inhibitor of MMPs 22-24
or vehicle alone for a total of 5 weeks followed by isolation
of skeletal muscle and performing H&E staining. As
shown in Figure 2A (top), there was no apparent difference in skeletal muscle structure of control mice treated
with vehicle or batimastat. Skeletal muscle of mdx mice
treated with vehicle alone showed typical features of
muscular dystrophy including the fibers of variable sizes,
central nucleation, increased area under necrosis, and
cellular infiltrates within muscle cross-sections (Figure
2A). However, the variability in fiber cross-sectional area,
the extent of degeneration/regeneration, and cellular infiltrates seems to be reduced in quadriceps and diaphragm on treatment of mdx mice with batimastat (Figure
2, A and B). Similar improvement in muscle structure was
also observed in gastrocnemius and soleus muscles of
batimastat-treated mdx mice (data not shown). Since repeated cycles of muscle degeneration and regeneration
and inflammation leads to the development of interstitial
fibrosis in skeletal muscle of mdx mice, we also determined whether treatment with batimastat can reduce
level of fibrosis in dystrophic muscle mdx mice. Staining
Batimastat Inhibits Pathology in mdx Mice
253
AJP July 2010, Vol. 177, No. 1
A
Vehicle
B
BB-94
C
*
200
100
70000
60000
50000
*
40000
30000
20000
10000
0
BB-94
Vehicle
Vehicle
BB-94
BB-94
Quadriceps
Diaphragm
Mdx
MMP’s enzymatic activity
(Relative light units)
Fiber size variability
300
Vehicle
D
Mdx
400
0
Quadriceps
Mdx
Quadriceps
Wild-type
500
Figure 2. Effects of chronic administration of batimastat on skeletal muscle structure and fibrosis in mdx mice. Starting at the age of two weeks, control and mdx
were given chronic administration of batimastat (BB-94) or vehicle alone for a total of five weeks as described in Materials and Methods. A: H&E staining of muscle
sections showed that batimastat did not affect skeletal muscle structure in control mice (top). Treatment with batimastat significantly improved muscle structure
in quadriceps (middle) and diaphragm (bottom) of mdx mice. B: Histogram shows variability in fiber diameter of diaphragm in mdx mice treated with vehicle
or BB-94. The data represent the mean of the SD of fibers. *P ⬍ 0.01, values significantly different from vehicle alone–treated mdx mice. N ⫽ 6 in each group.
Scale bar ⫽ 20 m. C: Data presented here show that the enzymatic activity of MMPs is significantly reduced in gastrocnemius muscle of BB-94-treated mdx mice
compared with vehicle alone treated mdx mice. *P ⬍ 0.05, values significantly different from wild-type mice (N ⫽ 4 in each group). D: Representative Sirius red
stained images show reduced fibrosis in quadriceps muscle of BB-94-treated mdx mice compared with those treated with vehicle alone. Scale bar ⫽ 20 m.
of quadriceps muscle sections with Sirius red dye (which
stains collagens) revealed considerably reduced fibrosis
in batimastat treated mdx mice compared with control
mice (Figure 2D). Finally, we also confirmed that treatment of mdx mice with batimastat significantly reduced
the enzymatic activity of MMPs in skeletal muscle of mdx
mice (Figure 2C). These data provide the initial evidence
that the inhibition of MMPs using batimastat reduces
skeletal muscle structural abnormalities and fibrosis in
mdx mice.
Batimastat Reduces the Accumulation of
Macrophages and the Expression of
Inflammatory Molecules in Skeletal Muscle of
mdx Mice
Inflammation is a major pathological feature that contributes significantly to the disease progression and fiber
necrosis in muscular dystrophy.38 – 41 To understand
whether increased levels of MMPs play a role in exacerbating inflammatory response in skeletal muscle of mdx
mice, we studied the accumulation of macrophages in
myofibers of vehicle and batimastat-treated mdx mice by
immunostaining muscle sections with Mac-1 antibody. As
shown in Figure 3A, treatment of mdx mice with batimastat reduced the concentration of macrophages in dystrophic muscles. To further confirm that batimastat decreases accumulation of macrophages in muscle tissues,
we also performed QRT-PCR to determine the mRNA
levels of Mac-1 and CD68, the major cell surface markers
for macrophages.20 Consistent with immunohistological
results, the mRNA levels of both Mac-1 and CD68 were
found to be significantly reduced in gastrocnemius muscle of batimastat-treated mdx mice compared with control
mice (Figure 3B) further suggesting that batimastat reduces the accretion of macrophages in dystrophic muscles of mdx mice.
Previously, reports have suggested that the expressions of various inflammatory cytokines, cell adhesion
molecules, and collagens are increased in skeletal muscle of mdx mice.7,8,42,43 By performing QRT-PCR, we
studied the expressions of a few inflammatory molecules in skeletal muscle of mdx mice. As shown in
Figure 3C, the mRNA levels of tumor necrosis factor
(TNF)-␣, intracellular cell adhesion molecule-1 (ICAM1), and vascular cell adhesion molecule-1 (VCAM-1)
were found to be significantly reduced in the skeletal
muscle of batimastat-treated mdx mice compared with
vehicle alone-treated mdx mice. Collagen I and collagen III are the major collagens present in extracellular
matrix of skeletal muscle and their levels are increased
in dystrophic muscle of mdx mice.20,44 Although the
level of collagen I (ie, Col1a1) was not affected, the
mRNA level of collagen III (ie, Col3a1) was found to
be significantly reduced on treatment of mdx mice with
batimastat (Figure 3C).
254
Kumar et al
AJP July 2010, Vol. 177, No. 1
A
B
Expression ratio
BB-94
Anti-Mac-1
Vehicle
Mac-1/β-actin
1.2
1.4
1.0
1.2
0.8
1.0
0.8
0.6
*
0.6
0.4
0.4
*
0.2
0.2
0.0
0.0
Vehicle BB-94
*
1.6
1.4
1.2
1.0
0.8
0.6
0.2
0.0
β-Actin MyHC
1.2
1.0
*
0.8
*
0.6
0.4
0.2
0.0
β-Actin
1.4
1.6
Col3a1 Expression ratio
Col1a1 Expression ratio
*
*
0.4
β-Actin MyHC
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
BB-94
VCAM-1 Expression ratio
Vehicle;
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
ICAM-1 Expression ratio
TNF-α Expression ratio
C
CD68/β-actin
1.2
1.0
MyHC
Vehicle BB-94
Figure 3. Effects of batimastat on the accumulation of macrophages and expression of inflammatory molecules in skeletal muscle of mdx
mice. A: Gastrocnemius muscle sections of vehicle or batimastat (BB-94)-treated mdx mice
were stained with Mac-1 antibody. Representative photomicrographs presented here show that
batimastat reduced the concentration of macrophages in mdx mice. N ⫽ 6 in each group. Scale
bar ⫽ 20 m. B: QRT-PCR analysis (normalized
to -actin) showed a significant reduction in the
mRNA levels of macrophage markers Mac-1 and
CD68 in gastrocnemius muscle of batimastattreated mdx (N ⫽ 4) mice compared with vehicle alone-treated mdx (N ⫽ 4) mice. C: Transcript levels of TNF-␣, ICAM-1, VCAM-1, and
Col3a1 but not Col1a1 were also found to be
significantly reduced in gastrocnemius muscle of
batimastat-treated mdx mice (N ⫽ 4) compared
with mdx mice given vehicle alone (N ⫽ 4). The
mRNA levels were normalized using -actin and
MyHC as housekeeping genes. *P ⬍ 0.01, values
significantly different from vehicle-alone treated
mdx mice.
0.8
0.6
*
*
0.4
0.2
0.0
β-Actin MyHC
β-Actin MyHC
Batimastat Reduces Fiber Necrosis and
Increases the Protein Levels of nNOS and
-Dystroglycan in Skeletal Muscle of mdx Mice
Dystrophin deficiency causes increased sarcolemmal
permeability and fiber necrosis.20,45 We next sought to
determine whether the inhibition of MMPs using batimastat can improve sarcolemma integrity and reduce fiber
necrosis in mdx mice. The permeable/necrotic fibers in
gastrocnemius muscle of mdx mice were quantified by
immunostaining the muscle sections with Cy3-labeled
anti-mouse IgG. As shown in Figure 4A, the mdx mice
treated with vehicle alone showed high intracellular staining for IgG within a part of their muscle fibers. However,
the number of IgG-stained muscle fibers was significantly
reduced in gastrocnemius muscle of mdx mice on treatment with batimastat (Figure 4, A and B).
Although the deficiency of dystrophin is the primary
cause for DMD, it has been consistently observed that
the loss of dystrophin perturbs the structural composition
of DGC in such a way that the levels of almost all of the
members of DGC and associated proteins are affected in
skeletal muscle fibers.46,47 It has also been reported that
the levels of utrophin, a homologue of dystrophin, are
increased in skeletal muscle of mdx mice, which may
account for reduced pathogenesis in mdx mice compared
with DMD patients.1,2,48,49 We investigated whether the inhibition of MMPs modulates the levels of various DGCrelated proteins. Interestingly, treatment with batimastat
significantly increased the levels of neuronal nitric oxide
synthase (nNOS) and -dystroglycan compared with
those treated with vehicle alone. In contrast, there was no
significant difference in levels of utrophin and ␣-dystrobrevin protein in batimastat-treated and vehicle alonetreated mdx mice (Figure 4, C and D).
Batimastat Reduces the Number of
Centronucleated Fibers and the Expression of
E-MyHC in Skeletal Muscle of mdx Mice
At the initial stages of disease progression, the necrotic
fibers in skeletal muscle of DMD patients or animal models are replaced by new myofibers depicted by increased number of centrally nucleated fibers. These
newly formed myofibers express E-MyHC and other
markers such as myogenin. Since fiber necrosis was
significantly reduced in batimastat-treated mdx mice, we
next sought to determine the effects of batimastat on the
formation of new myofibers in their skeletal muscle. Interestingly, the number of centronucleated fibers was significantly reduced in skeletal muscle of batimastattreated gastrocnemius muscle compared with vehicle
alone-treated mdx mice (Figure 5, A and B). Furthermore,
number of E-MyHC-stained myofibers was also considerably reduced in gastrocnemius muscle of batimastattreated mdx mice compared with those administered vehicle alone (Figure 5A), which was further confirmed by
Batimastat Inhibits Pathology in mdx Mice
255
AJP July 2010, Vol. 177, No. 1
A
B
16
BB-94
Cy3-labelled goat
anti-mouse IgG
% IgG-positive fibers
Vehicle
C
C57BL10
mice
Mdx mice
Vehicle
BB-94
14
12
10
8
6
*
4
2
0
Vehicle
BB-94
β-dystroglycan
nNOS
Utrophin
α-dystrobrevin
Tubulin
D
Relative density
2.5
β-dystroglycan
1.5
*
6
nNOS
Utrophin
2.0
1.0
1.5
*
4
3
3
2
0.5
2
1
0
0
C57BL10 Vehicle BB-94
mice
Mdx mice
1
0
C57BL10 Vehicle BB-94
mice
Mdx mice
α-dystrobrevin
5
4
1.0
0.5
7
6
5
Figure 4. Effects of batimastat on sarcolemmal
permeability and levels of cytoskeletal proteins
in mdx mice. A: Gastrocnemius muscle crosssections from vehicle alone or batimastat (BB94)-treated mdx mice were immunostained with
Cy3-labeled goat anti-mouse IgG to detect permeable/damaged fibers. B: Quantification of
Cy3-positive fibers showed a significant reduction in number of IgG permeable fibers in gastrocnemius muscle of batimastat-treated mdx
mice (N ⫽ 6) compared with mdx mice treated
with vehicle alone (N ⫽ 6). *P ⬍ 0.05, values
significantly different from mdx mice treated
with vehicle alone. Scale bar ⫽ 20 m. C: Tissue
extracts prepared from gastrocnemius muscle of
control mice and untreated or batimastat-treated
mdx mice were analyzed by Western blot. Representative immunoblots presented here show
that the levels of -dystroglycan and nNOS protein were considerably increased in batimastattreated mdx mice compared with vehicle alone–
treated mdx mice. The protein level of utrophin,
␣-dystrobrevin and an unrelated protein tubulin
remained unchanged. D: Quantification of Western blot (normalized with tubulin) showed a
significant increase in protein levels of -dystroglycan and nNOS but not utrophin or ␣-dystrobrevin in BB-94-treated mdx mice compared
with vehicle alone-treated mdx mice. *P ⬍ 0.01,
values significantly different from vehicle alonetreated mdx mice.
0
C57BL10 Vehicle BB-94
mice
Mdx mice
performing Western blot using E-MyHC antibody (Figure
5C). Moreover, the transcript level of myogenin was also
significantly lower in gastrocnemius muscle of batimastat-treated mdx mice compared with control mice (Figure
5D). The reduction in the number of centronucleated
fibers and E-MyHC-positive myofibers is consistent with
the reduced fiber degeneration and improvement in skeletal muscle structure in batimastat-treated mdx mice
compared with those treated with vehicle alone.
Batimastat Improves Skeletal Muscle Strength
in mdx Mice
Since batimastat was effective in reducing several pathological features in mdx mice, we investigated the effects
of batimastat on functional aspects of muscle by measuring force production in isometric contractions. We used
diaphragm muscle from wild-type and batimastat-treated
and corresponding vehicle alone–treated mdx mice for
these studies. Diaphragm was stimulated at different frequencies and absolute and specific muscle force produced in isometric contractions was measured. In agreement with reduced pathology in batimastat-treated mdx
mice, diaphragm force production was significantly
higher in batimastat-treated mdx mice compared with
vehicle alone–treated mice (Figure 6, A and B). The diaphragm muscle weight per unit area was also significantly reduced in batimastat-treated mdx mice compared
with those treated with vehicle alone (Figure 6C) further
indicating the reduction in muscle hypertrophy and pathology in batimastat-treated mdx mice.
C57BL10 Vehicle BB-94
mice
Mdx mice
Batimastat Inhibits the Activation of
Extracellular-Regulated Kinase 1/2 (ERK1/2),
p38 Mitogen-Activated Protein Kinase (MAPK),
and Activator Protein-1 (AP-1) in Skeletal
Muscle of mdx Mice
We have previously reported that the activation of ERK1/2
and AP-1 is significantly increased in skeletal muscle of mdx
mice.4 Published reports also suggest increased activation
of other MAPKs (eg, JNK1 and p38) at different stages of
disease progression in skeletal muscle of mdx mice.50 –53
Furthermore, it has been found that the activation of MAPKs
cause the pathogenesis not only in dystrophin-deficient
myofibers but also in several other types of muscular dystrophies.6 We investigated whether treatment with batimastat affects the activation of these signaling proteins in skeletal muscle of mdx mice. Consistent with previously
published reports,4,50 a significant increase in the levels of
phosphorylated ERK1/2 and p38 MAPK was observed in
gastrocnemius muscle of mdx mice compared with control
mice (Figure 7A). Interestingly, treatment of mdx mice with
batimastat reduced in the activation of both ERK1/2 and
p38MAPK in gastrocnemius muscle (Figure 7A). However,
we did not find any significant difference in the levels of
phosphorylated JNK1 in gastrocnemius muscle of mdx
mice compared with control mice. Furthermore, batimastat
did not affect the levels of JNK in gastrocnemius muscle of
mdx mice (Figure 7A).
The activation of MAPK generally leads to the downstream activation of various nuclear transcription factors,
256
Kumar et al
AJP July 2010, Vol. 177, No. 1
A
B
BB-94
Vehicle
Anti-E-MyHC
H&E
% Centronucleated fibers
45
35
Figure 5. Effects of batimastat on number of
centronucleated fibers and E-MyHC fibers in
skeletal muscle of mdx mice. A: Gastrocnemius
muscle sections of vehicle or batimastat (BB-94)treated mdx mice were stained with H&E or
embryonic/developmental myosin heavy chain
antibody. Representative photomicrographs presented here show that number of centronucleated and anti-EMyHC-stained fibers were considerable reduced in batimastat (BB-94)-treated
mdx mice compared with vehicle alone-treated
mdx mice. Scale bar ⫽ 20 m. B: Quantification
of centronucleated fibers showed significantly
reduced number in batimastat-treated mdx mice
(N ⫽ 6) compared with vehicle-alone treated
mdx mice (N ⫽ 7). *P ⬍ 0.05, values significantly
different from vehicle alone–treated mdx mice.
C: Representative immunoblots and quantification presented here show reduced levels of embryonic/developmental myosin heavy chain
protein in gastrocnemius muscle of batimastattreated mdx mice compared with vehicle alone–
treated mdx mice. *P ⬍ 0.01, values significantly
different from vehicle-treated mdx mice. D: The
mRNA level of myogenin (normalized with -actin or MyHC4) was significantly lower in gastrocnemius muscle of batimastat-treated mdx mice
(N ⫽ 4) compared with vehicle alone treated
mdx mice (N ⫽ 4). *P ⬍ 0.01, values significantly
different from vehicle alone–treated mdx mice.
30
25
*
20
15
10
5
0
Vehicle
C
Vehicle
1.2
1.0
0.8
Expression ratio
E-MyHC
1.4
Myogenin/β-actin 1.4
1.2
1.2
1.0
1.0
0.8
0.8
0.6
0.6
Myogenin/MyHC
*
0.6
*
0.4
0.4
0.2
0.2
0.0
0.4
BB-94
D
BB-94
Tubulin
Relative density
40
Vehicle BB-94
*
0.0
Vehicle BB-94
0.2
0
Vehicle
BB-94
the most prominent being AP-1.54 By performing electrophoretic mobility shift assay , we studied the effects of
batimastat on the activation of AP-1 in skeletal muscle of
mdx mice. The DNA-binding activity of AP-1 was considerably reduced in gastrocnemius muscle of batimastattreated mdx mice compared with those treated with vehicle alone (Figure 7B).
C
*
*
*
*
5
0
*
25
20
15
*
*
*
*
*
*
10
*
5
0
0
25
50
75 100 150 200 300
Frequency (Hz)
0
25
50
75 100 150 200 300
Frequency (Hz)
0.5
0.4
0.3
*
0.2
0.1
0
BB-94
10
*
Specific Force (N/cm2)
15
*
C57BL10
Mdx (BB-94)
Mdx (Vehicle)
30
Vehicle
C57BL10
Mdx (BB-94)
Mdx (Vehicle)
C57BL10
B
20
Absolute Force (N)
Many pathological conditions including muscular dystrophy are distinguished by uncontrolled matrix degradation
that results in excessive tissue destruction, disruption of
matrix boundaries, and loss of extracellular matrix functions. MMPs play critical role in extracellular matrix turn-
Diaphragm mass (mg/mm2)
A
Discussion
Mdx
Figure 6. Effects of batimastat on muscle strength in mdx mice. Data presented here show that average (A) absolute force; and specific force (B) produced by
diaphragm of batimastat-treated mdx mice was significantly higher as compared with mdx mice treated with vehicle alone. *P ⬍ 0.05, values significantly different
from corresponding mdx mice treated with vehicle alone at corresponding frequency. C: Diaphragm muscle weight per unit area was also significantly reduced
in BB-94-treated mdx mice compared with those treated with vehicle alone. *P ⬍ 0.05, values significantly different from vehicle alone-treated mdx mice.
Batimastat Inhibits Pathology in mdx Mice 257
AJP July 2010, Vol. 177, No. 1
C57BL10
mice
B
Mdx mice
Vehicle
BB-94
Phospho-ERK1/2
Free probe
A
C57BL10 Mdx mice
mice Vehicle BB-94
Total-ERK1/2
AP-1
Phospho-JNK1/2
Total-JNK1/2
Phospho-p38MAPK
Total-p38MAPK
Tubulin
Figure 7. Effect of batimastat on the activation
of MAPK and AP-1 in skeletal muscle of mdx
mice. A: Gastrocnemius muscle from control,
batimastat-treated, or untreated mdx mice were
isolated and tissue extracts made were analyzed
for the total and phosphorylated ERK1/2,
JNK1/2, and p38 MAPK. Data presented here
show that the levels of phosphorylated ERK1/2
and p38 MAPK were significantly reduced in
batimastat-treated mdx mice compared with vehicle alone–treated mdx mice. B: Representative
electrophoretic mobility shift assay gel presented here show that the DNA-binding activity
of AP-1 was significantly reduced in gastrocnemius muscle of batimastat-treated mdx mice
compared with mdx mice treated with vehicle
alone.
Free probe
over in physiological and pathological remodeling.11,18,19
The excessive production of MMPs is also strongly linked
with the initiation and perpetuation of inflammation and
fibrosis in various diseases.11,13–17 While muscular dystrophy involves considerable ECM abnormalities, the potential role of MMPs in the pathogenesis of muscular
dystrophy is less well known.
In this study, we tested the hypothesis that broad
inhibition of MMPs using pharmacological approaches
will be effective in alleviating the pathology of mdx mice.
Our results suggest that the expressions of a number of
MMPs are significantly increased in dystrophic muscle of
mdx mice (Table 1 and Figure 1). Our results also provide
compelling evidence that broad spectrum MMP inhibitory
drug batimastat, which has been used in several clinical
trials in cancer patients,19,29 –34 ameliorates pathology of
mdx mice. Although our study is a short-term where mdx
mice were treated only for 5 weeks and further investigations are required involving long-term treatment protocols
and higher animal models of DMD, it provides initial
evidence that MMPs may serve as important molecular
targets to alleviate the suffering of DMD patients.
Although the exact mechanisms by which increased
levels of MMPs contribute to disease progression in mdx
mice remain enigmatic, increased expression of MMPs in
skeletal muscle microenvironment may cause the breakdown of the components of cytoskeleton-ECM network
leading to sarcolemmal damage and fiber necrosis. Indeed, collagen IV (a major component of the basement
membrane) and -dystroglycan (an important protein of
DGC) have already been validated as the direct targets
of MMP-mediated proteolysis.11,12,55–57 In addition, several other proteins such as laminin, fibronectin, entactin,
and elastin present in ECM of skeletal muscle are also
potential proteolytic targets of various MMPs.58 – 60 Enhanced activity of MMPs may also cause the expression
and/or proteolytic activation of various latent inflammatory cytokines, chemokines, and growth factors leading
to inflammatory response and fibrosis in skeletal muscle.11 Indeed, these postulations are well supported by
our results that batimastat reduces the accumulation of
macrophages in muscle tissues, bring about a reduction
in the expression of proinflammatory cytokine TNF-␣, cell
adhesion molecules (ICAM-1 and VCAM-1), and fibrosisrelated gene Col3a1 (Figure 3), fiber necrosis (Figure 4),
and improves overall muscle structure and function in
mdx mice (Figures 2, 5, and 6).
We have also found that treatment with batimastat
reduces sarcolemmal damage and fiber necrosis in skeletal muscle of mdx mice (Figure 4A). Although the lack of
functional dystrophin is the primary cause for dystrophinopathy, the structural composition of the DGC and associated proteins is highly perturbed in skeletal muscle of
DMD patients and mdx mice.46,47 Our results demonstrate that batimastat significantly improves the levels of
-dystroglycan in skeletal muscle of mdx mice (Figure
4C), which is consistent with previously published reports
that -dystroglycan is proteolysed in MMP-dependent
manner in dystrophic muscle of mdx mice.55,56 Furthermore, the levels of nNOS, a protein that interacts with
DGC in skeletal muscle, is reduced in dystrophic muscles of mdx mice and restoration of nNOS ameliorates
muscle pathology in these mice.40 It is interesting to note
that nNOS is essential for maintenance of normal muscle
activity in vivo61 and genetic ablation of nNOS causes
significant reduction in maximum tetanic force production
and increases susceptibility to contraction-induced fatigue.62 Since treatment of mdx mice with batimastat
significantly enhanced protein levels of nNOS (Figure 4,
C and D) and improved muscle force production in isometric contractions in diaphragm of mdx mice (Figure 6),
elevated activity of MMPs may be one of potential reasons for the reduced levels of nNOS in dystrophic muscle
of mdx mice. However, it remains unknown how MMPs
affects the levels of nNOS in skeletal muscle of mdx mice.
Though nNOS does not directly interact with -dystroglycan in DGC (rather it interacts with ␣-syntrophin), one of
the possibilities could be that restoration of -dystroglycan level on MMP inhibition improves the overall stability
of DGC complex leading to increased expression of
DGC-interacting proteins including nNOS in skeletal
muscle. There is also a possibility that nNOS is directly
proteolysed by MMPs due to accumulation of active
MMPs in damaged/permeable myofibers of mdx mice.
258
Kumar et al
AJP July 2010, Vol. 177, No. 1
Furthermore, a recent report from our laboratory also
suggests that the protein (but not mRNA) levels of nNOS
are significantly reduced by overexpression of inflammatory cytokine TNF-like weak inducer of apoptosis in skeletal muscle of mice.63 Therefore, it is possible that the
reduced levels of nNOS are a result of increased inflammation in skeletal muscle of mdx mice and batimastat
augments nNOS protein levels by reducing inflammatory
response in mdx mice as supported by our results in this
study (Figure 3).
Another important finding of the present study was that
batimastat reduced the number of centronucleated myofibers and fibers expressing E-MyHC suggesting that skeletal muscle regeneration is attenuated on general inhibition
of MMPs in mdx mice. Since the treatment of mdx mice with
batimastat prevented fiber necrosis (Figures 2A, 4A, and
4B), the reduced number of centrally nucleated myofibers
and embryonic/developmental myosin heavy chain-positive
fibers may be a result of considerable reduction in fiber
necrosis/damage in batimastat-treated mdx mice eliminating the need for regeneration.
Accumulating evidence from our group and others suggests that lack of dystrophin leads to the activation of various proinflammatory signaling pathways and transcription
factors (eg, MAPKs, AP-1 and NF-B) leading to the increased levels of proinflammatory molecules.4,6 – 8,41,50 Furthermore, the activation of proinflammatory signaling pathways also occurs in macrophages which infiltrate skeletal
muscles of dystrophic animals.7 Our experiments demonstrate that batimastat suppresses the activation of MAPK
and their downstream phosphorylation target AP-1 in dystrophic muscle of mdx mice (Figure 7, A and B). Because
several proinflammatory cytokines and cell adhesion molecules including TNF-␣, ICAM-1, and VCAM-1 contain consensus AP-1 binding DNA sequences in their promoter/
enhancer region,54 the inhibition of AP-1 could also be one
of the potential reasons for their reduced expression in
skeletal muscle of batimastat-treated mdx mice.
Although our results suggest that batimastat is effective in reducing several pathological features in mdx
mice, it is important to note that batimastat (and its analogue marimastat) and several other first generation
broad spectrum MMP inhibitors failed in clinical trials
mainly due to a musculoskeletal syndrome that reduced
the overall quality of life for patients.18,64,65 While there is
no doubt that MMPs represent one of the most important
therapeutic targets for tissue degenerative disorders,
multiple reasons have been suggested for the failure of
first generation MMP inhibitory drugs (including batimastat) in clinical trials. A current theory is that the majority of
the side effects associated with MMP inhibitors in clinical
trials are predominantly related to off-target metal (Zn
and Fe) chelation from these drugs.66 The strongest evidence for musculoskeletal syndrome side effects not
being related to MMP inhibition per se comes from the
use of drugs that do not cause metal chelation. A number
of compounds have been reported to have the ability to
block MMP activity or expression including bisphosphonates,67,68 statins,69,70 and antibiotics.71 Of these, tetracycline-derivatives are the best studied with respect to
MMP inhibition.72,73 So far there is no evidence that treat-
ment with any of these drugs is associated with musculoskeletal syndrome, suggesting that new generation of
better designed MMP inhibitors will be more effective in
clinical trials.74 Consistent with our findings, Girgenrath
et al75 have recently reported that the treatment with tetracycline derivates doxycycline or minocycline improved
postnatal growth, delayed the onset of hind-limb paralysis, and increased the life span of the laminin-␣2-null
mice (a model of congenital muscular dystrophy) from
approximately 32 days to 70 days. Similarly, doxycycline
was effective in reducing the pathogenesis in a mouse
model of oculopharyngeal muscular dystrophy76 further
indicating that the pharmacological inhibition of MMPs
could be an important approach to enhance life span in
muscular dystrophy patients.
Because some of the MMPs also play critical roles in
various physiological processes, it is also important to
take into consideration that global inhibition of MMPs for
longer duration could lead to deleterious side effects. It
may be more beneficial to target specific MMPs that are
aberrantly regulated during disease progression. Though
the development of such methods is still in infancy, targeting MMPs only in affected tissues may also avoid the
associated side effects of inhibition of MMPs. Nevertheless, our present study demonstrating the efficacy of
batimastat in reducing skeletal muscle pathology in mdx
mice suggest that MMPs are potential drug targets for
treatment of DMD patients. Certainly, more investigations
are required to understand the effects of inhibition of
MMPs by multiple approaches in animal models before
considering MMPs as a therapeutic target for DMD
patients.
References
1. Emery AE: The muscular dystrophies. Lancet 2002, 359:687– 695
2. Campbell KP: Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 1995, 80:675– 679
3. Rando TA: The dystrophin-glycoprotein complex, cellular signaling,
and the regulation of cell survival in the muscular dystrophies. Muscle
Nerve 2001, 24:1575–1594
4. Kumar A, Khandelwal N, Malya R, Reid MB, Boriek AM: Loss of
dystrophin causes aberrant mechanotransduction in skeletal muscle
fibers. FASEB J 2004, 18:102–113
5. Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA,
Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM: The mdx
mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991, 352:536 –539
6. Bhatnagar S, Kumar A: Therapeutic targeting of signaling pathways in
muscular dystrophy. J Mol Med 2010, 88:155–166
7. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers
M, Li ZW, Beg AA, Ghosh S, Sahenk Z, Weinstein M, Gardner KL,
Rafael-Fortney JA, Karin M, Tidball JG, Baldwin AS, Guttridge DC: Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin
Invest 2007, 117:889 –901
8. Kumar A, Boriek AM: Mechanical stress activates the nuclear factorkappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. FASEB J 2003, 17:386 –396
9. Engvall E, Wewer UM: The new frontier in muscular dystrophy
research: booster genes. FASEB J 2003, 17:1579 –1584
10. Khurana TS, Davies KE: Pharmacological strategies for muscular
dystrophy. Nat Rev Drug Discov 2003, 2:379 –390
11. Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and
Batimastat Inhibits Pathology in mdx Mice
259
AJP July 2010, Vol. 177, No. 1
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007,
8:221–233
Vu TH, Werb Z: Matrix metalloproteinases: effectors of development
and normal physiology. Genes Dev 2000, 14:2123–2133
Chandler S, Miller KM, Clements JM, Lury J, Corkill D, Anthony DC,
Adams SE, Gearing AJ: Matrix metalloproteinases, tumor necrosis
factor and multiple sclerosis: an overview. J Neuroimmunol 1997,
72:155–161
Hu J, Van den Steen PE, Sang QX, Opdenakker G: Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007, 6:480 – 498
Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T,
Andersson PB, Stabler G, Miller K: Serum MMP-9 and TIMP-1 levels
are related to MRI activity in relapsing multiple sclerosis. Neurology
1999, 53:1397–1401
Hoyhtya M, Hujanen E, Turpeenniemi-Hujanen T, Thorgeirsson U,
Liotta LA, Tryggvason K: Modulation of type-IV collagenase activity
and invasive behavior of metastatic human melanoma (A2058) cells
in vitro by monoclonal antibodies to type-IV collagenase. Int J Cancer
1990, 46:282–286
Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SS, Liotta
LA: Expression of collagenase IV (basement membrane collagenase)
activity in murine tumor cell hybrids that differ in metastatic potential.
J Natl Cancer Inst 1985, 75:99 –103
Fingleton B: Matrix metalloproteinases as valid clinical targets. Curr
Pharm Des 2007, 13:333–346
Fingleton B: MMPs as therapeutic targets–still a viable option?. Semin
Cell Dev Biol 2008, 19:61– 68
Li H, Mittal A, Makonchuk DY, Bhatnagar S, Kumar A: Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves
skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet
2009, 18:2584 –2598
Raffetto JD, Khalil RA: Matrix metalloproteinases and their inhibitors in
vascular remodeling and vascular disease. Biochem Pharmacol
2008, 75:346 –359
Brown PD: Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 1995, 35:293–301
Rasmussen HS, McCann PP: Matrix metalloproteinase inhibition as a
novel anticancer strategy: a review with special focus on batimastat
and marimastat. Pharmacol Ther 1997, 75:69 –75
Grams F, Crimmin M, Hinnes L, Huxley P, Pieper M, Tschesche H,
Bode W: Structure determination and analysis of human neutrophil
collagenase complexed with a hydroxamate inhibitor. Biochemistry
1995, 34:14012–14020
Eccles SA, Box GM, Court WJ, Bone EA, Thomas W, Brown PD:
Control of lymphatic and hematogenous metastasis of a rat mammary
carcinoma by the matrix metalloproteinase inhibitor batimastat (BB94). Cancer Res 1996, 56:2815–2822
Lein M, Jung K, Le DK, Hasan T, Ortel B, Borchert D, Winkelmann B,
Schnorr D, Loenings SA: Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat
model. Prostate 2000, 43:77– 82
Low JA, Johnson MD, Bone EA, Dickson RB: The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer
solid tumor growth but not ascites formation in nude mice. Clin
Cancer Res 1996, 2:1207–1214
Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle
JD: Inhibition of organ invasion by the matrix metalloproteinase inhibitor
batimastat (BB-94) in two human colon carcinoma metastasis models.
Cancer Res 1995, 55:3629 –3633
Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart
RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M,
Fielding JW: Marimastat as maintenance therapy for patients with
advanced gastric cancer: a randomised trial. Br J Cancer 2002,
86:1864 –1870
Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JA:
Marimastat as first-line therapy for patients with unresectable pancreatic
cancer: a randomized trial. J Clin Oncol 2001, 19:3447–3455
Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels
JA: A double-blind placebo-controlled, randomised study comparing
gemcitabine and marimastat with gemcitabine and placebo as first
line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002, 87:161–167
Macaulay VM, O’Byrne KJ, Saunders MP, Braybrooke JP, Long L,
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
Gleeson F, Mason CS, Harris AL, Brown P, Talbot DC: Phase I study
of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res
1999, 5:513–520
Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown
P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D,
Millar A: Combined analysis of studies of the effects of the matrix
metalloproteinase inhibitor marimastat on serum tumor markers in
advanced cancer: selection of a biologically active and tolerable
dose for longer-term studies. Clin Cancer Res 1998, 4:1101–1109
Parsons SL, Watson SA, Steele RJ: Phase I/II trial of batimastat, a
matrix metalloproteinase inhibitor, in patients with malignant ascites.
Eur J Surg Oncol 1997, 23:526 –531
Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM: Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor
growth and spread in a patient-like orthotopic model in nude mice.
Cancer Res 1994, 54:4726 – 4728
Srivastava AK, Qin X, Wedhas N, Arnush M, Linkhart TA, Chadwick
RB, Kumar A: Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAK1)dependent signaling pathway. J Biol Chem 2007, 282:35113–35124
Dogra C, Changotra H, Mohan S, Kumar A: Tumor necrosis factor-like
weak inducer of apoptosis inhibits skeletal myogenesis through sustained activation of nuclear factor-kappaB and degradation of MyoD
protein. J Biol Chem 2006, 281:10327–10336
Spencer MJ, Tidball JG: Do immune cells promote the pathology of
dystrophin-deficient myopathies? Neuromuscul Disord 2001,
11:556 –564
Spencer MJ, Walsh CM, Dorshkind KA, Rodriguez EM, Tidball JG:
Myonuclear apoptosis in dystrophic mdx muscle occurs by perforinmediated cytotoxicity. J Clin Invest 1997, 99:2745–2751
Wehling M, Spencer MJ, Tidball JG: A nitric oxide synthase transgene
ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001,
155:123–131
Hnia K, Gayraud J, Hugon G, Ramonatxo M, De La Porte S, Matecki
S, Mornet D: L-arginine decreases inflammation and modulates the
nuclear factor-kappaB/matrix metalloproteinase cascade in mdx
muscle fibers. Am J Pathol 2008, 172:1509 –1519
Wehling-Henricks M, Lee JJ, Tidball JG: Prednisolone decreases
cellular adhesion molecules required for inflammatory cell infiltration
in dystrophin-deficient skeletal muscle. Neuromuscul Disord 2004,
14:483– 490
Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds
CR, Leahy P, Li J, Guo W, Andrade FH: A chronic inflammatory
response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 2002, 11:263–272
Wehling-Henricks M, Sokolow S, Lee JJ, Myung KH, Villalta SA,
Tidball JG: Major basic protein-1 promotes fibrosis of dystrophic
muscle and attenuates the cellular immune response in muscular
dystrophy. Hum Mol Genet 2008, 17:2280 –2292
Straub V, Rafael JA, Chamberlain JS, Campbell KP: Animal models
for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol 1997, 139:375–385
Ohlendieck K, Campbell KP: Dystrophin-associated proteins are
greatly reduced in skeletal muscle from mdx mice. J Cell Biol 1991,
115:1685–1694
Ohlendieck K, Matsumura K, Ionasescu VV, Towbin JA, Bosch EP,
Weinstein SL, Sernett SW, Campbell KP: Duchenne muscular
dystrophy: deficiency of dystrophin-associated proteins in the sarcolemma. Neurology 1993, 43:795– 800
Dalkilic I, Kunkel LM: Muscular dystrophies: genes to pathogenesis.
Curr Opin Genet Dev 2003, 13:231–238
Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, Davies
K: Expression of full-length utrophin prevents muscular dystrophy in
mdx mice. Nat Med 1998, 4:1441–1444
Hnia K, Hugon G, Rivier F, Masmoudi A, Mercier J, Mornet D: Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical
scavenger administration in dystrophin-deficient Mdx mice. Am J
Pathol 2007, 170:633– 643
Nakamura A, Yoshida K, Takeda S, Dohi N, Ikeda S: Progression of
dystrophic features and activation of mitogen-activated protein ki-
260
Kumar et al
AJP July 2010, Vol. 177, No. 1
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
nases and calcineurin by physical exercise, in hearts of mdx mice.
FEBS Lett 2002, 520:18 –24
Nakamura A, Yoshida K, Ueda H, Takeda S, Ikeda S: Up-regulation of
mitogen activated protein kinases in mdx skeletal muscle following
chronic treadmill exercise. Biochim Biophys Acta 2005, 1740:326 –331
Kolodziejczyk SM, Walsh GS, Balazsi K, Seale P, Sandoz J, Hierlihy
AM, Rudnicki MA, Chamberlain JS, Miller FD, Megeney LA: Activation
of JNK1 contributes to dystrophic muscle pathogenesis. Curr Biol
2001, 11:1278 –1282
Karin M: The regulation of AP-1 activity by mitogen-activated protein
kinases. J Biol Chem 1995, 270:16483–16486
Matsumura K, Zhong D, Saito F, Arai K, Adachi K, Kawai H, Higuchi
I, Nishino I, Shimizu T: Proteolysis of beta-dystroglycan in muscular
diseases. Neuromuscul Disord 2005, 15:336 –341
Michaluk P, Kolodziej L, Mioduszewska B, Wilczynski GM, Dzwonek
J, Jaworski J, Gorecki DC, Ottersen OP, Kaczmarek L: Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal
activity. J Biol Chem 2007, 282:16036 –16041
Zhong D, Saito F, Saito Y, Nakamura A, Shimizu T, Matsumura K:
Characterization of the protease activity that cleaves the extracellular
domain of beta-dystroglycan. Biochem Biophys Res Commun 2006,
345:867– 871
Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T: Regulation
of matrix metalloproteinases: an overview. Mol Cell Biochem 2003,
253:269 –285
Das S, Mandal M, Chakraborti T, Mandal A, Chakraborti S: Structure
and evolutionary aspects of matrix metalloproteinases: a brief overview. Mol Cell Biochem 2003, 253:31– 40
Lewis MP, Machell JR, Hunt NP, Sinanan AC, Tippett HL: The extracellular matrix of muscle–implications for manipulation of the craniofacial musculature. Eur J Oral Sci 2001, 109:209 –221
Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR,
Faulkner JA, Parikh SV, Weiss RM, Chamberlain JS, Moore SA,
Campbell KP: Sarcolemma-localized nNOS is required to maintain
activity after mild exercise. Nature 2008, 456:511–515
Percival JM, Anderson KN, Gregorevic P, Chamberlain JS, Froehner
SC: Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. PLoS ONE 2008, 3:e3387
Mittal A, Bhatnagar S, Kumar A, Lach-Trifilieff E, Wauters S, Li H,
Makonchuk DY, Glass DJ, Kumar A: The TWEAK-Fn14 system is a
critical regulator of denervation-induced skeletal muscle atrophy in
mice, J Cell Biol 2010, 188:833– 849
Brown PD: Clinical studies with matrix metalloproteinase inhibitors.
APMIS 1999, 107:174 –180
65. Dove A: MMP inhibitors: glimmers of hope amidst clinical failures. Nat
Med 2002, 8:95
66. Renkiewicz R, Qiu L, Lesch C, Sun X, Devalaraja R, Cody T, Kaldjian
E, Welgus H, Baragi V: Broad-spectrum matrix metalloproteinase
inhibitor marimastat-induced musculoskeletal side effects in rats.
Arthritis Rheum 2003, 48:1742–1749
67. Giraudo E, Inoue M, Hanahan D: An amino-bisphosphonate targets
MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114:623– 633
68. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S,
Salesi N, Giannarelli D, Alimonti A, Di Cocco B, D’Agosto G,
Bordignon V, Trento E, Cognetti F: Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and
proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005, 69:35– 43
69. Yasuda S, Miyazaki S, Kinoshita H, Nagaya N, Kanda M, Goto Y,
Nonogi H: Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment
in patients with acute myocardial infarction. Clin Sci (Lond) 2007,
112:43– 49
70. Wilson WR, Evans J, Bell PR, Thompson MM: HMG-CoA reductase
inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in
abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2005,
30:259 –262
71. Acharya MR, Venitz J, Figg WD, Sparreboom A: Chemically modified
tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist
Updat 2004, 7:195–208
72. Saikali Z, Singh G: Doxycycline and other tetracyclines in the treatment of bone metastasis. Anticancer Drugs 2003, 14:773–778
73. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T:
Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms. Adv Dent Res 1998, 12:12–26
74. Abramovici H, Hogan AB, Obagi C, Topham MK, Gee SH: Diacylglycerol kinase-zeta localization in skeletal muscle is regulated by
phosphorylation and interaction with syntrophins. Mol Biol Cell 2003,
14:4499 – 4511
75. Girgenrath M, Beermann ML, Vishnudas VK, Homma S, Miller JB:
Pathology is alleviated by doxycycline in a laminin-alpha2-null model
of congenital muscular dystrophy. Ann Neurol 2009, 65:47–56
76. Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O’Donovan
DG, Rubinsztein DC: Doxycycline attenuates and delays toxicity of
the oculopharyngeal muscular dystrophy mutation in transgenic
mice. Nat Med 2005, 11:672– 677